This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Bayer to Pay $14.2B for Merck OTC Unit

Stocks in this article: MRK GSK NVS PFE AZN

BERLIN (The Deal) -- Germany's Bayer on Tuesday agreed to buy the over-the-counter business of Merck (MRK) as major deals continue to reshape the global pharmaceutical landscape.

The Leverkusen, Germany-based company said it would pay $14.2 billion to add Claritin allergy medications and Dr. Scholls footcare products to its arsenal of non-prescription treatments.

"With this transaction, we are acquiring leading product brands that will make Bayer the over-the-counter leader in North America and Latin America and also move us into top global positions in key over-the-counter product categories," said Bayer HealthCare CEO Olivier Brandicourt in a statement.

Bayer Snares Merck Unit as Global Indices Waver
More videos from Brittany Umar

Global drug companies are feverishly opening their wallets to expand in what they see as their key businesses. The deal will make Bayer the world's No. 2 non-prescription drugs company behind London's GlaxoSmithKline (GSK), which is currently folding its OTC activities into those of Basel-based Novartis (NVS).

The deal between Glaxo and Novartis also has Novartis buying Glaxo's oncology business in exchange for Novartis' vaccines. Novartis is also selling its animal health unit to Indianapolis-based Eli Lilly and Co. Meanwhile, New York's Pfizer (PFE) is trying to spend 63.1 billion pounds ($107 billion) to buy London-based AstraZeneca (AZN) and become an oncology heavyweight.

Bayer late last month became the perceived winner in the auction for the Merck business after the U.K.'s Reckitt Benckiser said it was no longer in talks with Merck.

The purchase price represents a proforma multiple of 21 times 2013 Ebitda, according to Bayer. The Merck activities last year had sales of $2.2 billion and the German buyer expects to eke out $200 million in annual synergies by 2017 and boost sales by an additional $400 million a year by expanding Merck's brands outside the U.S.

Bayer is founding corporate father of OTC remedies after one of its scientists discovered aspirin in the 19th century. The company began beefing up its non-prescription division in 2004 with the 2.4 billion euro ($3.3 billion) acquisition of Roche Holding's OTC business.

Then, earlier this year, it further expanded the retail division with an agreement for Chinese OTC and herbal medicine specialist Dihon Pharmaceutical Group Co. Ltd. No price was given in that deal but Dihon has annual sales of 123 million euros ($171.4 million).

OTC drugs isn't the only business that has caught Bayer's eye: in February the company succeeded with its 17.6 billion Norwegian kroner ($3 billion) offer for Norwegian partner Algeta. Algeta and Bayer have jointly developed a prostate cancer treatment.

But the Merck purchase is Bayer's largest since it paid 16.3 billion euros in 2006 as part of a white-knight bid for Berlin's Schering that made it the world's biggest contraceptive manufacturer.

Bayer said it would finance the deal initially with a loan from Bank of America Merrill Lynch, BNP Paribas SA and Mizuho Bank Ltd. The loan will eventually be syndicated and the company said it would also potentially turn to capital markets.

The acquisition is expected to close in the second half of this year.

To finance the purchase, Bayer may also peddle its plastics division. The company is rumored to be shopping the unit, known as its material science division, which analysts say could fetch more than $10 billion.

Bayer shares slipped 0.81 euro to 99.14 euros in afternoon Frankfurt trading.

Morgan Stanley and JPMorgan Securities acted as financial advisers to Merck, with a Fried Frank Harris Shriver & Jacobson LLP team including David Shine and Abigail Bomba and Morgan Lewis & Bockius LLP's Alan Leeds, Randall Sunberg, David Glazer serving as counsel in connection with the transaction.

--David Marcus contributed to this report.

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs